Pfizer’s Paxlovid Misses On Prevention, But Impact Limited

A Phase II/III trial testing Paxlovid as a preventative treatment for COVID-19 failed to show a statistically significant efficacy benefit.

Pfizer Inc.'s COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) failed to show a benefit in a Phase II/III trial for post-exposure prophylactic (PEP) use, but the company is stressing that it does not impact its use as a treatment for people already infected with COVID-19 who are at high risk of hospitalization.

A fuller view of the long-term opportunity will come from the company’s first quarter sales and earnings report on 3...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip